Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators
Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
1. A method for treating a host having anti-estrogen resistant breast cancer, comprising administering to said host tamoxifen and a selective Retinoid X Receptor (RXR) modulator, wherein the tamoxifen and the selective RXR modulator are administered in amounts that together are pharmaceutically effective, and thereby treating a host having anti-estrogen resistant breast cancer.
2. The method of claim 1 , wherein said selective RXR modulator is selected from the group consisting of LGD1069, LGD100268 and LGD100324.
3. The method of claim 1 , wherein said selective RXR modulator selectively activates one or more RXRs in preference to each of RAR isoforms α, β and γ.
4. The method of claim 1 , wherein the tamoxifen and the selective RXR modulator are administered at the same time.
5. The method of claim 1 , wherein the host having anti-estrogen resistant breast cancer has previously been treated with an anti-estrogen compound.
6. The method of claim 1 , wherein the host having anti-estrogen resistant breast cancer has previously been treated with tamoxifen.
7. The method of claim 1 , wherein the anti-estrogen resistant breast cancer is capable of growing in the presence of at least one anti-estrogen compound.
8. A method for treating a host having tamoxifen resistant breast cancer, comprising administering to said host tamoxifen and a selective RXR modulator, wherein the tamoxifen and the selective RXR modulator are administered in amounts that together are pharmaceutically effective.
9. The method of claim 8 , wherein said selective RXR modulator is selected from the group consisting of LGD1069, LGD100268, and LGD100324.
10. The method of claim 8 , wherein said selective RXR modulator selectively activates one or more RXRs in preference to each of RAR isoforms α, β, and γ.
11. The method of claim 8 , wherein the tamoxifen and the selective RXR modulator are administered at the same time.
12. The method of claim 8 , wherein the host having tamoxifen resistant breast cancer has previously been treated with an anti-estrogen compound.
13. The method of claim 8 , wherein the host having tamoxifen resistant breast cancer has previously been treated with tamoxifen.
14. The method of claim 8 , wherein the tamoxifen resistant breast cancer is capable of growing in the presence of at least one anti-estrogen compound.
15. A method for treating a host having anti-estrogen resistant breast cancer, comprising administering to said host a pharmaceutically effective amount of a composition comprising tamoxifen and a selective RXR modulator.
16. A method for treating a host having tamoxifen resistant breast cancer, comprising administering to said host a pharmaceutically effective amount of a composition comprising tamoxifen and a selective RXR modulator.
17. A method for improving the efficacy of treating a host having anti-estrogen resistant breast cancer with tamoxifen, comprising administering to said host a pharmaceutically effective amount of a selective RXR modulator.
18. A method for improving the efficacy of treating a host having tamoxifen resistant breast cancer with tamoxifen, comprising administering to said host a pharmaceutically effective amount of a selective RXR modulator.